ARTICLE

Judyta Cielecka-Piontek, Marianna Zając, Anna Jelińska

Dorypenem - najnowszy analog karbapenemu
2009-03-25

Doripenem is a new parenteral 1-methyl carbapenem, which was launched in the European Union on July 25, 2008, by the EMEA. Doripenem is licensed from Shionogi & Co., LTd, which launched the product in Japan in September 2005. The chemical structure of doripenem is very similar to that of meropenem. Doripenem, like all the other beta-lactams, exhibits its bactericidal effects by binding to penicillin-binding proteins. It has a spectrum of activity that covers aerobic and anaerobic gram-positive and gram-negative bacteria. It can be used as a single agent for the treatment of infections caused by Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Acinetobacter baumanni and Pseudomonas spp. Doripenem has been approved to treat complicated intra-abdominal infection and, complicated urinary tract infections, including pyelonenephritis, nosocomial and respiratory infections. The recommended dose of doripenem is 500 mg every 8 hours given as an IV infusion over 1 hour. The duration of therapy, which may include a switch to an oral agent after at least 3 days of parenteral therapy, is 5 to 14 days.
Keywords: carbapenems, dorypenem.

Dorypenem - najnowszy analog karbapenemu

335.51 kB | 21 grudnia 2017